Twist Bioscience Corporation (TWST) – What Are Researchers Thinking About This Stock?

Shares of Twist Bioscience Corporation (NASDAQ:TWST) have been given a consensus recommendation of “Hold” by the thirteen brokerages that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $143.67.

A number of equities research analysts have issued reports on TWST shares. UBS Group began coverage on Twist Bioscience in a research note on Wednesday, September 9th. They set a “neutral” rating and a $144.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Monday, September 21st. Jefferies Financial Group assumed coverage on shares of Twist Bioscience in a report on Thursday, October 8th. They issued a “hold” rating and a $150.00 price objective on the stock. Guggenheim raised their price objective on shares of Twist Bioscience from $107.00 to $212.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Finally, Evercore lowered shares of Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 target price for the company. in a research report on Monday, July 6th.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, SVP Paula Green sold 10,088 shares of the stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total value of $1,905,421.44. Following the transaction, the senior vice president directly owned 106,632 shares in the company, valued at approximately $20,140,652.16. This trade represents a 8.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Emily M. Leproust sold 356,546 shares of Twist Bioscience stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $157.99, for a total transaction of $56,330,702.54. Following the transaction, the chief executive officer owned 620,589 shares in the company, valued at $98,046,856.11. This represents a 36.49% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 601,920 shares of company stock valued at $93,768,202 over the last three months. Insiders own 3.08% of the company’s stock.

Hedge Funds Weigh In On Twist Bioscience

A number of institutional investors have recently bought and sold shares of TWST. E. Ohman J or Asset Management AB bought a new stake in Twist Bioscience during the second quarter valued at about $853,000. Allspring Global Investments Holdings LLC purchased a new stake in Twist Bioscience in the first quarter worth about $22,563,000. Bank of America Corp DE increased its position in Twist Bioscience by 46.3% in the first quarter. Bank of America Corp DE now owns 584,261 shares of the company’s stock worth $27,764,000 after buying an additional 184,907 shares in the last quarter. William Blair Investment Management LLC purchased a new stake in Twist Bioscience in the second quarter worth about $223,722,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Twist Bioscience in the second quarter worth about $8,215,000.

Twist Bioscience Stock Performance

Shares of TWST opened at $145.25 on Tuesday. The firm has a market capitalization of $9.11 billion, a P/E ratio of -65.43 and a beta of 2.19. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. Twist Bioscience has a one year low of $23.30 and a one year high of $219.71. The business has a fifty day moving average of $150.30 and a 200 day moving average of $86.26.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The firm had revenue of $118.38 million during the quarter, compared to the consensus estimate of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The firm’s revenue was up 23.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.33 EPS. As a group, sell-side analysts anticipate that Twist Bioscience will post -2.12 EPS for the current year.

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.

Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.